Last update May 19, 2021

Ebastine

Very Low Risk

Safe. Compatible. Minimal risk for breastfeeding and infant.

Second generation anti-histaminic and piperidine drug with a slightly sedative effect.
It is indicated in the symptomatic treatment of allergic rhinitis and pruritic skin disorders.
Oral administration once daily.

It is excreted in breast milk in clinically insignificant amounts and no problems have been observed in infants whose mothers have taken it . Plasma levels in these infants were very low (Saito 2020).

Its high percentage of plasma protein binding and very high volume of distribution (Cuvillo 2006) explain the negligible passage into milk observed.

Second generation anti-histaminic medicines are considered to be safe while breastfeeding (So 2010, Leimgruber 2007, Solhaug 2004).

Alternatives

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Ebastine in other languages or writings:

Group

Ebastine belongs to this group or family:

Tradenames

Main tradenames from several countries containing Ebastine in its composition:

Pharmacokinetics

Variable Value Unit
Molecular weight 469 daltons
Protein Binding > 95 %
VD > 100 l/Kg
pKa 16.45 -
Tmax 2.6 - 4 hours
13.8 - 19 hours
M/P ratio 4.5 -
Theoretical Dose 0.001 mg/Kg/d
Relative Dose 0.57 %

References

  1. Saito J, Yakuwa N, Sandaiji N, Yagishita S, Kawasaki H, Suzuki T, Ozawa K, Kamura S, Yamatani A, Wada S, Sago H, Murashima A. Ebastine during pregnancy and lactation in a patient with chronic urticaria: ebastine and carebastine levels in maternal serum, cord blood, breast milk and the infant's serum. J Eur Acad Dermatol Venereol. 2020 Sep;34(9):e496-e497. Abstract
  2. Teva. Ebastine. Drug Summary. 2020 Full text (in our servers)
  3. AEMPS. Ebastina. Ficha técnica. 2017 Full text (in our servers)
  4. So M, Bozzo P, Inoue M, Einarson A. Safety of antihistamines during pregnancy and lactation. Can Fam Physician. 2010 May;56(5):427-9. Abstract Full text (link to original source) Full text (in our servers)
  5. Leimgruber A. [Treatment of asthma and rhinitis during pregnancy and breast feeding]. Rev Med Suisse. 2007 Abstract
  6. del Cuvillo A, Mullol J, Bartra J, Dávila I, Jáuregui I, Montoro J, Sastre J, Valero AL. Comparative pharmacology of the H1 antihistamines. J Investig Allergol Clin Immunol. 2006;16 Suppl 1:3-12. Review. No abstract available. Abstract Full text (link to original source) Full text (in our servers)
  7. Solhaug V, Roland PD. Bruk av antihistaminer under graviditet og amming \ [Use of antihistaminics during pregnancy and breast feeding]. Tidsskr Nor Laegeforen. 2004 Abstract Full text (link to original source) Full text (in our servers)
  8. Yamaguchi T, Hashizume T, Matsuda M, Sakashita M, Fujii T, Sekine Y, Nakashima M, Uematsu T. Pharmacokinetics of the H1-receptor antagonist ebastine and its active metabolite carebastine in healthy subjects. Arzneimittelforschung. 1994 Jan;44(1):59-64. Abstract

Total visits

131,202

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by IHAN of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM